

Q1 FY27 Earnings Call

October 29, 2026

Presentation of financial information & forward-looking statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc. ("Resmed"), its subsidiaries, and its legal entities for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Gross Profit, non-GAAP Gross Margin, non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.Resmed.com).

In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Resmed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, the execution of strategic initiatives, leveraging of strategic investments, litigation, and outlook. The words "believe," "expect," "intend," "anticipate," "will continue," "will," "estimate," "plan," "future" and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, the integration of acquisitions, the execution of strategic initiatives, our , domestic and international regulatory developments, litigation, outlook, and the expected impact of macroeconomic conditions on our business.

We have not included a reconciliation for forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.

Resmed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements due to risks, uncertainties, and other factors. Resmed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in Resmed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

Q1 FY27 Results

\$1.4B

Total Revenue
6% HL / 7% Core¹ CC YoY growth

62.5%

Non-GAAP Gross Margin
+50 basis points YoY

\$2.91


Non-GAAP EPS
14% YoY growth

>\$1B

Capital returned
to shareholders²

Continued commitment to build the world's leading digital health ecosystem

Resmed key areas of focus



Key areas of focus that will continue contributing to Resmed's growth and transformation

Q1 Innovation updates

Expanding Device & Fabric Mask Platforms

AirCurve™ 11 ST / ST-A

US bilevel launch for complex sleep apnea & overlap syndrome (OSA + COPD) built on our market-leading Air11 platform



AirTouch™ F40

US launch; 3rd fabric mask; ComfiSoft™ cushion adapts through the night. **91% rated it comfortable at initial fitting**¹



AirTouch™ N30i


Demonstrated a **+6% increase in 90-day compliance** over AirFit™ N30i




Driving Resupply Through Refreshed Patient Experience

myAir™

Personalized: new myAir Score, Nightly Timeline, Therapy Control & **Equipment Care**² resupply reminders



2.1M+
Dawn GenAI coach inquiries (up 40%)





Personalized AI-Powered Compliance

Smart Comfort (FDA-cleared)

Used Resmed's sleep data to adjust comfort settings

4.3% increase in 30-day compliance vs. default settings

TIME Best Inventions 2026 – Special Mention



Operational improvements and developments

Gross Margin

Ahead

of Q1 FY27 expectations; benefited from phasing of supply chain expansion investments

Multi-year

robust initiative pipeline

Double-digit

bps GM improvement every year through 2030

US Productivity Flexibility

1st

Made in America PAP: AirSense 11 (Atlanta)



AS11 Line at Atlanta Site

Indiana

new distribution center for faster delivery in the US



External Indy site view

Global Manufacturing Footprint



Production lines

We continue to invest in **expanding our capabilities** to serve our patients across **140+ countries**



Automated motor assembly line

Expanding access to sleep health through key partnerships



Connecting sleep insights and expanding access to sleep health resources

Pathway explained:


- Brings together Eight Sleep and Resmed **sleep insights in one experience**
- Gain broader **visibility** into **sleep health** and **sleep trends** over time
- Access **sleep health education, resources**, and **assessment tools** to learn more about sleep health and available support options



Enhancing sleep health awareness and education while improving access to care


Pathway explained:

- **Identify:** Signs of nighttime **breathing disturbances** are surfaced in the ÖURA app
- **Assess:** Members **access Resmed sleep education** and **complete the Resmed Sleep Assessment**
- **Connect:** Members **explore care options** through “Find a Clinic” or “Virtual Care”



Resmed + ÖURA Early KPIs:


~28K Resmed.com visits
~72% of assessment takers undiagnosed



Real-world data analysis now shows >3.3M patients on GLP-1s both initiate CPAP more and stay on therapy

Patients with an OSA diagnosis **and** prescribed a GLP-1 drug are **more likely** to initiate PAP therapy and have **higher PAP resupply rates**

GLP-1 initiated^{1,2} vs. non-GLP-1 initiated OSA patients¹



Large real-world data analysis: n = 3,307,000 patients⁵ with GLP-1 initiation, sleep apnea diagnosis, and Rx for PAP therapy⁶

Note: CPAP + GLP-1 and CPAP-only cohorts are measured on the same basis: patients who stop CPAP remain in the base population for both.

Source: IQVIA LRX data and Diagnostic claims, July 2021 – June 2026.

¹ Total patients with an OSA diagnosis claim from July 2021 – June 2026; those who were diagnosed with OSA prior to July 2021 are not included in this analysis.

² GLP-1 initiation is defined by presence of GLP-1 claim at any point from July 2021 – June 2026 (n=3,307k patients); initiation does not demonstrate GLP-1 treatment adherence, so patients may not be actively taking GLP-1s today.

³ Values show absolute percentage difference in presence of any PAP-related claim from July 2021 – June 2026 comparing OSA patients who used GLP-1s versus OSA patients with no GLP-1 use.

⁴ Values show absolute percentage difference in presence of any PAP-related claim at each timepoint post PAP setup from July 2021 – June 2026 comparing OSA patients who used GLP-1s versus OSA patients with no GLP-1 use.

⁵ Patient counts have been updated to reflect additional claims data from IQVIA.

⁶ Majority of patients in the analysis population were prescribed newer GLP-1 drugs: semaglutide or tirzepatide.

Q1 Marketing is expanding awareness and improving patient lives

CPAP Baddies

Normalizing CPAP through

- 1) **cultural** relevance,
- 2) **community-led** social growth,
- and 3) **expanding into category conversation**



“In Bed With” Series

Series of conversations positioning Resmed as a **trusted, culturally relevant voice** at the **intersection of sleep, performance, and health**

Olympic athlete, filmmaker and author Alexi Pappas and sleep physician Cheri D. Mah, MD, MS discussing **sleep-driven, peak performance**:




Athlete Partnerships

Our partnership with Tyler Reddick and 23XI Racing brings the **sleep health conversation to a new audience**

“The **ones benefitting most** (from Tyler being on therapy) are **me and my kids**... his presence is **more productive, more engaging**, Tyler is (now) **more of a team player**, and a **dad**”

– Alexa, Tyler’s wife, on Tyler’s CPAP journey



Clinicians are highly engaged with Resmed education programs focused on sleep

✓ ~108,000 CME courses completed



✓ By >63,000 unique clinicians



✓ With ~75% Saying they intend to change their clinical practices with regards to OSA



Prioritizing higher-growth, higher-return opportunities

MatrixCare Business¹ Divestiture

Closed September 1, 2026 

Strategic Rationale

- ✓ Accelerates **growth and profitability** of core RCS
- ✓ FY27 RCS outlook reiterated: **high single-digit revenue growth**, with **operating leverage**
- ✓ **Improved mix and sharper execution focus**

Nidra Acquisition

Closed June 1, 2026 

Strategic Rationale

- ✓ Commercial footprint **expanding rapidly**
- ✓ Good **early integration progress**
- ✓ **Priority: expand commercial coverage** and patient access



Nidra is a novel, non-invasive therapy for restless legs syndrome (RLS); acquired via Noctrix Health

Record shareholder returns; confident in our 5-year outlook

Shareholder Returns

- ✓ **Record >\$1B¹** returned to shareholders in Q1 FY27
- ✓ **~\$936M** in buybacks, incl. **ASR** funded by MatrixCare business² divestiture proceeds
- ✓ **High ROI** conviction in investing in Resmed

5-Year Global Outlook

**High single-digit
% Revenue Growth**

**Earnings growth
higher than
revenue growth**

Why we are confident:


- + Tremendous **market opportunity**
- + **Leading** market position
- + Very **strong** balance sheet
- + Proven **execution track record**, anchored by our 2030 strategy

Q1

Financial Results and FY 2027 Guidance




Q1 FY27 Global revenue results




Note: Data as of September 30, 2026. Resmed's fiscal year end is June 30th. All \$ in millions, unless noted otherwise.
Note: All growth rates are year-over-year on a core constant currency (CCC) basis. RoW = Rest of World.
Note: Year-over-year core constant currency metrics by segment for FY26 are provided in the Appendix.
¹ The remaining Residential Care Software business – Brightree and MEDIFOX Dan – increased by 8%.

Q1 FY27 Rest of P&L

Non-GAAP Gross Margin




Non-GAAP Operating Margin




Non-GAAP Earnings Per Share

(\$ in actuals)



Free Cash Flow¹

(\$ in millions)



Reiterating FY27 Revenue guidance

5% – 7%

YoY Core CC Revenue Growth
Includes ~130 bps (or) ~\$75M
headwind from Astral

\$5.75B – \$5.85B

HL Total Revenue

For FY27 & FY26:

- Only 2 months of MatrixCare revenue **included**
- Nidra revenue **excluded**

For FY27:

- Only 2 months of MatrixCare revenue **included**
- Nidra revenue **included**
- Now assumes FX headwind of **~60 bps** (vs. ~50)

Key assumptions underpinning guidance:

1

Net price realization as we continue to roll out pricing increases globally

2

Successful execution of our marketing campaigns


3

2H FY27 pressure in our RoW sleep devices as France fleet renewal concludes

4

External environment, including continued inflationary impact

Reiterating FY27 Fully diluted non-GAAP EPS guidance



Reiterating FY27 P&L margin outlook

Non-GAAP Gross Margin




**Low-double-digit
basis point expansion**
for FY27 vs. FY26;
with variability quarter-to-quarter

Non-GAAP Operating Margin



Slight increase
for FY27 vs. FY26;
productivity and efficiency-driven

Disciplined capital allocation strategy supports both business growth *and* return of capital to shareholders



Q2 FY27 Preliminary trends

Total Revenue Growth (%)

Mid-single-digit QoQ increase¹

Non-GAAP Gross Margin (%)

Slightly down QoQ

R&D Expenses (\$)

Roughly flat QoQ

SG&A Expenses (% Change)

Up low-single-digit QoQ

Net Other Income (\$)

Down ~\$10 million QoQ

Q1 FY27 Progress in key business priorities

Growth



- Investing in the highest-ROI R&D and marketing initiatives
- Optimizing the patient experience
- Converting new patients entering the funnel
- Expanding the sleep opportunity

Transformation



- Driving efficiencies
- Active portfolio management
- Selectively evaluating M&A
- Leveraging AI and technology to transform and improve productivity

Shareholder Returns



- Returned >\$1B to shareholders this quarter
- Enhanced transparency
- Commitment to dividend and opportunistic buybacks
- Evaluating capital structure

Contact Investor Relations

Phone: +1 (858) 221-3304

Email: InvestorRelations@Resmed.com

Website: Investor.Resmed.com



APPENDIX

Q1 – Q4 FY26 Global core constant currency revenue growth

		Revenue \$				Core CC growth %			
		Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Americas	Sleep Devices	\$405	\$438	\$436	\$452	9%	10%	7%	8%
	Life Support Devices	\$9	\$10	\$11	\$7	(27%)	(41%)	(29%)	(45%)
RoW	Sleep Devices	\$250	\$266	\$276	\$281	6%	6%	9%	13%
	Life Support Devices	\$17	\$12	\$12	\$10	9%	(15%)	(30%)	(38%)

Unmatched scale in connected respiratory & digital health

More than **29 billion nights** of respiratory medical data (up ~1B)



39+ million
patients in AirView™



Up ~1M



36+ million
100% cloud connectable devices worldwide



Up ~1M



4.9+ million
diagnostic tests processed in the cloud



Up ~0.1M



13.2+ million
patients have signed up for myAir™




Up ~0.7M



460+ API
calls per second from integrators

Large, underpenetrated total addressable market = long runway for growth



MARKET FOR DEVICES

Growing in the mid-single digits globally

MARKET FOR MASKS

Growing in the high-single digits globally

Underpenetrated OSA Market¹

<20%
U.S.

<10%
Rest of World

OSA patients diagnosed or treated

U.S. OSA Prevalence to Increase²

~77M
adults by 2050

↗ ~35%
From 2020

GLP-1s impact limited (4%)

DRIVERS

Aging | Higher average BMIs |
65% relative increase in prevalence in women

Key megatrends are driving patients and providers to Resmed's ecosystem



Consumers are more **focused on their health** than ever before



Widespread adoption of GLP-1 medications **increases awareness of sleep apnea**




Wearables spotlight **sleep apnea and sleep quality in general**



Consumers demand an **elevated experience** for healthcare products



AI and digital health are changing how healthcare is delivered



Massive pressure on healthcare systems; **payers / providers are laser-focused on preventative care¹**

¹Study published in SLEEP in 2026 involving 370k+ patients (including those with co-existing chronic diseases COPD, type 2 diabetes, depression, heart failure, and atrial fibrillation) and the medXcloud academic-industry collaborative, found (a) a consistent, dose-dependent reduction in hospitalizations and ER visits across all 5 comorbidity groups; (b) benefits emerging at just 2 to <4 hours of average nightly PAP use; (c) each additional hour of PAP use linked to a 4.1-6.2% reduction in healthcare utilization over 12-24 months ($p < 0.0001$).

Reconciliation of non-GAAP financial measures

In addition to financial information prepared in accordance with GAAP, we use certain non-GAAP financial measures, such as non-GAAP core constant currency basis, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.

The non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide our detailed reconciliations to the corresponding GAAP financial measures) are adjusted for the impact of acquisitions and divestitures, amortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment-related expenses, gains on divestment of subsidiaries, and associated tax effects, in addition to the tax effect of interest and penalties on tax refunds.

We have not included a reconciliation of forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.

Non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages):

Reconciliation of non-GAAP financial measures (cont'd)

(Unaudited; \$ in millions, except for per share amounts)

	Three Months Ended	
	September 30, 2026	September 30, 2025
GAAP total revenue growth	6 %	9 %
Impact of:		
Acquisitions/divestitures ^(A)	1	—
Effect of foreign currency fluctuations ^(A)	—	(1)
Non-GAAP core constant currency total revenue growth	7 %	8 %

Note regarding non-GAAP reconciliations

(A) In order to provide a framework for assessing how our underlying businesses performed excluding the impact of the Noctrix acquisition and the divestiture of the MatrixCare business and the effect of foreign currency fluctuations, when applicable, we provide certain financial information on a “core constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

Reconciliation of non-GAAP financial measures (cont'd)

(Unaudited; \$ in millions, except for per share amounts)

Three Months Ended September 30, 2026										
	Gross profit	Research and development expenses	Selling, general, and administrative expenses	Income from operations	Total other income (loss), net	Income tax expense	Net income	Diluted earnings per share		
GAAP	\$ 871	\$ 103	\$ 315	\$ 453	\$ 86	\$ 121	\$ 418	\$ 2.92		
Amortization of acquired intangibles	5	—	(8)	14	—	4	10	0.07		
Restructuring and business transformation expenses	8	(1)	(20)	29	—	7	22	0.16		
Acquisition and divestment related expenses	—	—	(10)	10	—	—	10	0.07		
Gain on divestment of subsidiary	—	—	—	—	(62)	(7)	(55)	(0.38)		
Income tax effect of interest income on tax refunds	—	—	—	—	—	(12)	12	0.07		
Non-GAAP ^(A)	\$ 884	\$ 102	\$ 276	\$ 506	\$ 24	\$ 113	\$ 418	\$ 2.91		

Note regarding non-GAAP reconciliations

(A) Totals may not add due to rounding.

Reconciliation of non-GAAP financial measures (cont'd)

(Unaudited; \$ in millions, except for per share amounts)

Three Months Ended September 30, 2025									
	Gross profit	Research and development expenses	Selling, general, and administrative expenses	Income from operations	Total other income (loss), net	Income tax expense	Net income	Diluted earnings per share	
GAAP	\$ 818	\$ 89	\$ 282	\$ 447	\$ —	\$ 98	\$ 349	\$ 2.37	
Amortization of acquired intangibles	8	—	(12)	20	—	5	15	0.10	
Restructuring and business transformation expenses	3	(2)	(10)	16	—	4	12	0.08	
Non-GAAP ^(A)	\$ 829	\$ 87	\$ 259	\$ 482	\$ —	\$ 108	\$ 375	\$ 2.55	

Note regarding non-GAAP reconciliations

(A) Totals may not add due to rounding.

Reclassification of Prior-period Amounts

During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. In connection with this change, we renamed "restructuring expenses" as "restructuring and business transformation expenses" to reflect the broader nature of the costs included within this category. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses.

Prior-period amounts have been reclassified to conform to the current-period presentation. The reclassifications had no effect on previously reported income from operations, income before income taxes, net income, earnings per share or cash flows.

Reclassification of Prior-period Amounts (cont'd)

(Unaudited; \$ in thousands)

The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):

	Three Months Ended September 30, 2025			
	As previously reported	Restructuring and business transformation expenses	Amortization of acquired intangibles	As reclassified
Cost of sales - Sleep and Breathing Health products	\$ 456,118	\$ 3,156	\$ 1,420	\$ 460,694
Cost of sales - Residential Care Software	50,823	—	6,401	57,224
Cost of sales (exclusive of amortization shown separately below)	\$ 506,941	\$ 3,156	\$ 7,821	\$ 517,918
Amortization of acquired intangible assets - Sleep and Breathing Health products	1,420	—	(1,420)	—
Amortization of acquired intangible assets - Residential Care Software	6,401	—	(6,401)	—
Amortization of acquired intangible assets	\$ 7,821	\$ —	\$ (7,821)	\$ —
Total cost of sales	\$ 514,762	\$ 3,156	\$ —	\$ 517,918
Gross profit	\$ 820,820	\$ (3,156)	\$ —	\$ 817,664
Research and development	87,323	2,156	—	89,479
Selling, general, and administrative	259,194	10,498	11,956	281,648
Amortization of acquired intangible assets	11,956	—	(11,956)	—
Restructuring expenses	15,810	(15,810)	—	—
Total operating expenses	\$ 374,283	\$ (3,156)	\$ —	\$ 371,127
Income from operations	\$ 446,537	\$ —	\$ —	\$ 446,537

Reclassification of Prior-period Amounts (cont'd)

(Unaudited; \$ in thousands)

The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):

	Three Months Ended December 31, 2025			
	As previously reported	Restructuring and business transformation expenses	Amortization of acquired intangibles	As reclassified
Cost of sales - Sleep and Breathing Health products	\$ 484,792	\$ 994	\$ 1,415	\$ 487,201
Cost of sales - Residential Care Software	51,484	—	6,393	57,877
Cost of sales (exclusive of amortization shown separately below)	\$ 536,276	\$ 994	\$ 7,808	\$ 545,078
Amortization of acquired intangible assets - Sleep and Breathing Health products	1,415	—	(1,415)	—
Amortization of acquired intangible assets - Residential Care Software	6,393	—	(6,393)	—
Amortization of acquired intangible assets	\$ 7,808	\$ —	\$ (7,808)	\$ —
Total cost of sales	\$ 544,084	\$ 994	\$ —	\$ 545,078
Gross profit	\$ 878,724	\$ (994)	\$ —	\$ 877,730
Research and development	90,969	1,233	—	92,202
Selling, general, and administrative	278,396	3,708	11,764	293,868
Amortization of acquired intangible assets	11,764	—	(11,764)	—
Restructuring expenses	5,935	(5,935)	—	—
Total operating expenses	\$ 387,064	\$ (994)	\$ —	\$ 386,070
Income from operations	\$ 491,660	\$ —	\$ —	\$ 491,660

Reclassification of Prior-period Amounts (cont'd)

(Unaudited; \$ in thousands)

The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):

	Three Months Ended March 31, 2026			
	As previously reported	Restructuring and business transformation expenses	Amortization of acquired intangibles	As reclassified
Cost of sales - Sleep and Breathing Health products	\$ 481,722	\$ —	\$ 1,421	\$ 483,143
Cost of sales - Residential Care Software	50,855	—	6,429	57,284
Cost of sales (exclusive of amortization shown separately below)	\$ 532,577	\$ —	\$ 7,850	\$ 540,427
Amortization of acquired intangible assets - Sleep and Breathing Health products	1,421	—	(1,421)	—
Amortization of acquired intangible assets - Residential Care Software	6,429	—	(6,429)	—
Amortization of acquired intangible assets	\$ 7,850	\$ —	\$ (7,850)	\$ —
Total cost of sales	\$ 540,427	\$ —	\$ —	\$ 540,427
Gross profit	\$ 890,979	\$ —	\$ —	\$ 890,979
Research and development	94,267	—	—	94,267
Selling, general, and administrative	285,655	—	11,247	296,902
Amortization of acquired intangible assets	11,247	—	(11,247)	—
Restructuring expenses	—	—	—	—
Total operating expenses	\$ 391,169	\$ —	\$ —	\$ 391,169
Income from operations	\$ 499,810	\$ —	\$ —	\$ 499,810

Reclassification of Prior-period Amounts (cont'd)

(Unaudited; \$ in thousands)

The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):

	Three Months Ended June 30, 2026			
	As previously reported	Restructuring and business transformation expenses	Amortization of acquired intangibles	As reclassified
Cost of sales - Sleep and Breathing Health products	\$ 539,975	\$ —	\$ 2,011	\$ 541,986
Cost of sales - Residential Care Software	54,155	—	6,290	60,445
Cost of sales (exclusive of amortization shown separately below)	\$ 594,130	\$ —	\$ 8,301	\$ 602,431
Amortization of acquired intangible assets - Sleep and Breathing Health products	2,011	—	(2,011)	—
Amortization of acquired intangible assets - Residential Care Software	6,290	—	(6,290)	—
Amortization of acquired intangible assets	\$ 8,301	\$ —	\$ (8,301)	\$ —
Total cost of sales	\$ 602,431	\$ —	\$ —	\$ 602,431
Gross profit	\$ 861,216	\$ —	\$ —	\$ 861,216
Research and development	105,726	—	—	105,726
Selling, general, and administrative	296,283	—	10,499	306,782
Amortization of acquired intangible assets	10,499	—	(10,499)	—
Restructuring expenses	—	—	—	—
Total operating expenses	\$ 412,508	\$ —	\$ —	\$ 412,508
Income from operations	\$ 448,708	\$ —	\$ —	\$ 448,708